Last updated: February 23, 2026
What is NDC 75907-0129?
NDC 75907-0129 is a drug marketed as Baricitinib, primarily used for the treatment of rheumatoid arthritis. It gained recent prominence for being authorized in COVID-19 treatment protocols in certain contexts. The drug is marketed under brand names such as Olumiant by Eli Lilly and Company.
Market Overview
Therapeutic Area
- Primary indication: Rheumatoid arthritis (RA)
- Additional uses: COVID-19 management (emergency use authorization in some regions)
- Market size (2022): Estimated global sales ~$800 million, driven by RA and COVID-19 applications.
Competitive Landscape
- Main competitors: Tofacitinib (Xeljanz), Upadacitinib (Rinvoq), Baricitinib has moderate market share.
- Patent status: Patent protection expiring in key markets in 2026-2028; generic entry anticipated post-expiry.
- Regulatory status: Approved by FDA, EMA, and other healthcare agencies; COVID-19 indication granted via emergency protocols.
Current Market Dynamics
- Increased adoption driven by recent approvals for COVID-19.
- Growing prevalence of RA globally, especially in aging populations.
Pricing and Reimbursement
| Region |
List Price (per month) |
Reimbursement Status |
| U.S. |
$2,500–$3,000 |
Insurance coverage, pharmacy benefit managers (PBMs) covering >70% of patients |
| Europe |
€1,800–€2,400 |
Reimbursed by national health schemes in major markets |
| Japan |
¥300,000–¥350,000 |
National health insurance covers substantial portion |
Price points remain variable due to negotiations, discounts, and healthcare system differences.
Price Trends and Projections (2023–2028)
Short-term (2023–2024)
- Prices are expected to remain stable with minor adjustments for inflation and regulatory changes.
- COVID-19 related indications could sustain or slightly increase demand, influencing prices regionally.
Medium-term (2025–2026)
- Patent expiration likely around 2026-2028 may lead to increased price competition.
- Biosimilar development progress influences average selling prices (ASPs).
Long-term (2027–2028)
- Entry of biosimilars post-patent expiry expected to reduce list prices by 20–40%.
- Market shares shift towards biosimilars and generics, reducing average prices.
Influencing Factors
- Regulatory approvals and reimbursement policies.
- Manufacturing costs and supply chain stability.
- Adoption rates driven by clinical guidelines and physician acceptance.
- Competitive landscape with biosimilars and alternative therapies.
Price Impact of Biosimilars Post-Patent Expiry
| Scenario |
Expected Price Reduction |
Key Assumptions |
| Moderate biosimilar entry |
25–30% less than branded |
At least one biosimilar approved and marketed |
| Multiple biosimilars |
40–50% less |
Market consolidates with multiple entrants |
Investment and R&D Outlook
- Eli Lilly and competitors continue R&D into next-generation JAK inhibitors.
- Market consolidation may occur as biosimilar landscape matures.
- Pricing pressures may prompt preemptive discounts and patient assistance programs.
Key Takeaways
- NDC 75907-0129 (Baricitinib) holds a significant role in RA treatment, with escalating relevance for COVID-19.
- The current list price in major markets ranges from $2,500 to $3,000 monthly.
- Patent expiry predicted around 2026-2028 will trigger biosimilar competition, reducing prices.
- Short-term pricing stability may persist, but long-term projections indicate substantial price erosion.
- Market share will shift in favor of biosimilars once available, paralleling trends observed with other biologics and targeted therapies.
FAQs
1. When will biosimilars for NDC 75907-0129 become available?
Biosimilars are expected to receive approval post-patent expiration, likely around 2026-2028.
2. How does the price of Baricitinib compare to its competitors?
Compared to Tofacitinib and Upadacitinib, Baricitinib’s list price is similar or slightly lower, but market dynamics vary by region and insurance coverage.
3. What are key factors influencing future price declines?
Introduction of biosimilars, market competition, patent expiration, and negotiated reimbursement prices.
4. What impact has COVID-19 had on the market for NDC 75907-0129?
The COVID-19 indication temporarily increased demand, supporting higher use in certain regions, though the primary driver remains RA treatment.
5. Are there anticipated regulatory changes affecting pricing?
Yes, regulatory reviews on drug pricing transparency, biosimilar approvals, and reimbursement policies could influence future pricing strategies.
References
- Food and Drug Administration. (2022). FDA Approval of Baricitinib.
- Eli Lilly and Company. (2022). Olumiant product information.
- IQVIA. (2022). Global Market Data for Rheumatoid Arthritis Therapeutics.
- Europe Medicines Agency. (2022). Baricitinib summary review.
- Market Research Future. (2023). Biosimilar Market Analysis and Outlook.
